Bristol-Myers Squibb vs Pfizer: Strategic Comparison
Direct Answer
Pfizer is the bigger company by revenue, reporting $62.579 billion for fiscal 2025 against Bristol Myers Squibb's $48.194 billion, and it employs roughly 75,000 people versus BMS's 32,500. Bristol Myers Squibb is the more profitable of the two by margin: its $7.054 billion of 2025 net earnings equaled a 14.6% net margin, ahead of Pfizer's 12.4% margin on $7.771 billion of net income. By market value, Pfizer was worth about $157.7 billion as of September 18, 2026, versus roughly $130.2 billion for Bristol Myers Squibb as of September 10, 2026, according to Macrotrends.
Pfizer and Bristol Myers Squibb are unusual rivals: the two drugmakers co-commercialize the world's top-selling anticoagulant, Eliquis, even as they compete directly in oncology, immunology and dealmaking elsewhere. Pfizer, founded in Brooklyn in 1849, reported $62.579 billion of revenue and $7.771 billion of net income for fiscal 2025, with about 75,000 employees and Albert Bourla as chairman and CEO since January 1, 2019. Bristol Myers Squibb, formed by the 1989 merger of companies dating to 1858 and 1887, reported $48.194 billion of revenue and $7.054 billion of net earnings for 2025, with about 32,500 employees under CEO Chris Boerner, who took over in November 2023. Pfizer has nearly double BMS's headcount, but BMS converts a larger share of each sales dollar into profit.
Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.
Key Differences at a Glance
| Field | Bristol-Myers Squibb Company | Pfizer Inc. |
|---|---|---|
| Latest annual revenue | $48.2B (FY2025) | $62.6B (FY2025) |
| Founded | 1887 | 1849 |
| Employees | 32,500 | 75,000 |
| Market Cap | $127.5B | $160.3B |
| Headquarters | United States | United States |
| Revenue / Employee | $1.48M / employee | $834k / employee |
| Valuation Multiple | 2.6x P/S | 2.6x P/S |
Strategic Positioning
Business model and competitive context from the cited profiles
Bristol-Myers Squibb Company Strategic Vector
FY2025 Revenue BaselineBristol-Myers Squibb Company's long-term commercial strategy prioritizes scaling high-margin growth vectors while actively mitigating structural industry risks. In terms of growth initiatives, management is allocating capital toward neuroscience and new modalities, where cobenfy could add Alzheimer's disease psychosis if the ADEPT trials succeed, and BMS has positions in radiopharmaceuticals (RayzeBio), in vivo CAR-T for autoimmune disease (Orbital) and PD-(L)1 x VEGF bispecifics (BNT327 with BioNTech). Concurrently, the organization focuses on navigating market pressures around us drug pricing policy, addressing environments where about 69 percent of revenue is from the United States. By maintaining disciplined capital allocation and operational rigor, Bristol-Myers Squibb Company aims to protect its unit economics and preserve its economic moat across changing market cycles.
Pfizer Inc. Strategic Vector
FY2025 Revenue BaselineFollowing the historic pandemic revenue windfall, Pfizer's corporate strategy centers on redeploying capital into high-growth oncology franchises and structural cost alignment. Under Chief Executive Officer Albert Bourla, Pfizer executed the landmark forty-three-billion-dollar acquisition of Seagen Inc., instantly establishing Pfizer as a global powerhouse in targeted cancer therapies. Seagen added four commercialized antibody-drug conjugates (including Padcev, Adcetris, and Tukysa) and doubled Pfizer's oncology pipeline with specialized tumor-homing molecules. Concurrently, Pfizer launched a multi-billion-dollar enterprise cost realignment program to adjust operating expenses to post-pandemic baseline demand, while launching novel vaccines including Abrysvo for respiratory syncytial virus (RSV) protection in infants and older adults.
Quick Stats Comparison
| Metric | Bristol-Myers Squibb Company | Pfizer Inc. |
|---|---|---|
| Revenue | $48.2B (FY2025) | $62.6B (FY2025) |
| Founded | 1887 | 1849 |
| Headquarters | Princeton, New Jersey | New York, New York |
| Market Cap | $127.5B | $160.3B |
| Employees | 32,500 | 75,000 |
| Revenue / Employee | $1.48M / employee | $834k / employee |
| Valuation Multiple | 2.6x P/S | 2.6x P/S |
Bristol-Myers Squibb Revenue vs Pfizer Revenue — Year by Year
| Year | Bristol-Myers Squibb Company | Pfizer Inc. | Higher reported revenue |
|---|---|---|---|
| 2025 | $48.2B | $62.6B | Pfizer Inc. (approx. USD) |
| 2024 | $48.3B | $63.6B | Pfizer Inc. (approx. USD) |
| 2023 | $45.0B | $59.6B | Pfizer Inc. (approx. USD) |
| 2022 | $46.2B | $101.2B | Pfizer Inc. (approx. USD) |
| 2021 | $46.4B | $81.3B | Pfizer Inc. (approx. USD) |
Business Model Breakdown
Overview: Bristol-Myers Squibb Company vs Pfizer Inc.
This in-depth comparison examines Bristol-Myers Squibb Company and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bristol-Myers Squibb Company on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bristol-Myers Squibb Company and Pfizer Inc. is widest.
On the headline numbers, annual revenue is $48.2B (FY2025) for Bristol-Myers Squibb Company and $62.6B (FY2025) for Pfizer Inc., while their respective market capitalizations stand at $127.5B and $160.3B. Both Bristol-Myers Squibb Company and Pfizer Inc. are headquartered in United States. Their local markets and applicable rules may still differ.
Bristol-Myers Squibb Company: Bristol Myers Squibb (BMS) is a U.S. biopharmaceutical company headquartered in Princeton, New Jersey, and listed on the New York Stock Exchange as BMY. It develops and sells prescription medicines for cancer, blood disorders, immune diseases, heart disease and schizophrenia. Its best-known products are Eliquis, the anticoagulant it sells with Pfizer, and Opdivo, a PD-1 checkpoint inhibitor. With $48.2 billion of 2025 revenue and a market value of about $127 billion at the end of September 2026, it is one of the largest U.S. drugmakers by sales. The massive biopharmaceutical titan was formed in New York City, New York through the 1989 mega-merger of two historic drug companies, eventually becoming an absolute powerhouse in modern cancer immunology.
Pfizer Inc.: Pfizer Inc. (NYSE: PFE) is one of the largest pharmaceutical companies in the world by revenue, headquartered at The Spiral, 66 Hudson Boulevard East, New York. It employs about 75,000 people and sells medicines in more than 180 countries. Its history includes Terramycin, Lipitor (via Warner-Lambert), Viagra, Prevnar (via Wyeth) and the Comirnaty COVID-19 vaccine developed with BioNTech. The company is headquartered in New York City, New York. Pfizer was founded in 1849 in Brooklyn, New York City, by German immigrant cousins Charles Pfizer and Charles F. Erhart as a fine-chemicals business, expanding over 175 years into a global biopharmaceutical giant discovering penicillin, Lipitor, Viagra, and the landmark COVID-19 vaccine Comirnaty.
Business Models: How Bristol-Myers Squibb Company and Pfizer Inc. Make Money
Bristol-Myers Squibb Company and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bristol-Myers Squibb Company and Pfizer Inc..
Bristol-Myers Squibb Company business model: Bristol Myers Squibb Company (BMS) discovers, develops, and delivers innovative medicines across four core therapeutic areas: Oncology, Hematology, Cardiovascular, and Immunology. Commercial revenues are categorized into a Legacy Blockbuster Portfolio and a high-growth New Product Portfolio. The Legacy portfolio includes Eliquis (apixaban, leading oral anticoagulant co-marketed with Pfizer), Opdivo (nivolumab, anti-PD-1 cancer immunotherapy), Pomalyst, and Revlimid. The New Product Portfolio comprises next-generation therapies including Camzyos (mavacamten for obstructive hypertrophic cardiomyopathy), Opdualag (fixed-dose nivolumab and relatlimab for melanoma), Breyanzi (CD19-directed CAR-T cell therapy), Reblozyl (erythroid maturation agent), Sotyktu (oral allosteric TYK2 inhibitor for psoriasis), and Cobenfy (xanomeline and trospium chloride for schizophrenia).
Pfizer Inc. business model: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology. Historically recognized for blockbuster small molecules (Lipitor, Viagra, Eliquis) and pediatric vaccines (Prevnar family), Pfizer achieved unprecedented revenue scale by co-developing Comirnaty—the world's first authorized mRNA COVID-19 vaccine—with BioNTech, alongside the oral antiviral Paxlovid. The company monetizes intellectual property through global pharmaceutical distribution networks, selling to national governments, hospital purchasing organizations, and retail pharmacy chains across more than one hundred twenty countries.
Competitive Advantage: Bristol-Myers Squibb Company vs Pfizer Inc.
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bristol-Myers Squibb Company stack up against those of Pfizer Inc..
Bristol-Myers Squibb Company competitive advantage: Bristol Myers Squibb's competitive moat is founded on deep clinical leadership in immuno-oncology, pioneering CAR-T cell therapy manufacturing, and a first-in-class neuroscience mechanism for psychiatric disorders. By discovering and developing Opdivo and Yervoy, BMS pioneered dual checkpoint inhibition in oncology. Through the $14 billion acquisition of Karuna Therapeutics, BMS secured Cobenfy—the first antipsychotic medication with a novel mechanism of action (targeting muscarinic cholinergic receptors rather than dopamine D2 receptors) approved in more than 30 years, giving BMS exclusive commercial runway in psychiatric medicine. BMS's cell therapy manufacturing facilities in Massachusetts, Washington, and the Netherlands provide proprietary viral vector and CAR-T engineering capabilities.
Pfizer Inc. competitive advantage: Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities. Few pharmaceutical corporations in the world possess the logistical capacity to conduct concurrent Phase 3 clinical trials involving tens of thousands of patients across dozens of countries while managing ultra-low-temperature cold-chain distribution. Pfizer's Prevnar pneumococcal conjugate vaccine family has maintained multi-decade commercial dominance due to the extreme complexity of polysaccharide-protein conjugation manufacturing. Pfizer's alliance with Bristol-Myers Squibb on the anticoagulant Eliquis provides reliable, high-margin cash flow, while its commercial relationships with national healthcare authorities enable rapid global drug rollouts.
Growth Strategy: Where Bristol-Myers Squibb Company and Pfizer Inc. Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Bristol-Myers Squibb Company and Pfizer Inc. each plan to expand from here.
Bristol-Myers Squibb Company growth strategy: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.
Pfizer Inc. growth strategy: Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total). Obesity: Pfizer acquired Metsera in November 2025 for about $10 billion including contingent value rights, after a bidding contest with Novo Nordisk. Cost: a multi-year cost realignment and manufacturing optimization program funds R&D and protects margins.
Financial Picture: Bristol-Myers Squibb Company vs Pfizer Inc.
A closer look at the financial trajectory of Bristol-Myers Squibb Company and Pfizer Inc. rounds out the comparison.
Bristol-Myers Squibb Company: Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion. Bristol Myers Squibb is a dominant force in global biopharmaceuticals, sustaining a massive market valuation that regularly exceeds $100 billion.
Pfizer Inc.: Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.
Company-Specific SWOT Notes
Bristol-Myers Squibb Company
Eliquis ($14.4 billion) and Opdivo ($10.0 billion) produced about half of 2025 revenue and help fund roughly $12.8 billion of annual free cash flow, a dividend raised 17 years running and continued deal-making.
Newer brands such as Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag and Cobenfy grew 17 percent to $26.4 billion in 2025 and were nearly 60 percent of revenue by the second quarter of 2026.
Eliquis and Opdivo both lose U.S. exclusivity in 2028, and Revlimid, Pomalyst and Sprycel are already losing sales to generics.
The Celgene, MyoKardia, Karuna, Mirati and RayzeBio deals left about $47.2 billion of debt at the end of 2025 and produced GAAP net losses in 2020 and 2024 from in-process R&D charges.
Cobenfy could add Alzheimer's disease psychosis if the ADEPT trials succeed, and BMS has positions in radiopharmaceuticals (RayzeBio), in vivo CAR-T for autoimmune disease (Orbital) and PD-(L)1 x VEGF bispecifics (BNT327 with BioNTech).
About 69 percent of revenue is from the United States.
Pfizer Inc.
Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.
Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.
The impending loss of exclusivity for blockbuster drugs like Eliquis and Ibrance threatens a significant portion of Pfizer's high-margin recurring revenue by 2027.
The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.
Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.
Factual Scorecard
| Category | Result | Why |
|---|---|---|
| Same-period Revenue Scale | Pfizer Inc. | $48.2B (FY2025) versus $62.6B (FY2025); the higher figure is identified after approximate USD conversion. |
| Founded Earlier | Pfizer Inc. | Bristol-Myers Squibb Company was founded in 1887; Pfizer Inc. was founded in 1849. |
Comparison Takeaway: Bristol-Myers Squibb vs Pfizer
Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.
Frequently Asked Questions: Bristol-Myers Squibb vs Pfizer
Is Pfizer bigger than Bristol Myers Squibb?
Yes, by revenue and headcount. Pfizer reported $62.579 billion of revenue for fiscal 2025, about 30% more than Bristol Myers Squibb's $48.194 billion, and employed roughly 75,000 people against BMS's 32,500. Pfizer was also the more valuable company, at about $157.7 billion in market capitalization as of September 18, 2026, versus roughly $130.2 billion for BMS as of September 10, 2026.
Which is more profitable, Pfizer or Bristol Myers Squibb?
Bristol Myers Squibb has the higher net margin. Its $7.054 billion of 2025 net earnings on $48.194 billion of revenue works out to a 14.6% margin, versus Pfizer's 12.4% margin on $7.771 billion of net income and $62.579 billion of revenue. BMS also generated about $1.48 million of revenue per employee in 2025, nearly 78% more than Pfizer's roughly $834,000.
Who is the CEO of Pfizer and Bristol Myers Squibb?
Albert Bourla has been Pfizer's chairman and CEO since January 1, 2019. Chris Boerner has led Bristol Myers Squibb as CEO since November 2023 and became board chair on April 1, 2024, succeeding Giovanni Caforio.
Why do Pfizer and Bristol Myers Squibb both sell Eliquis?
Pfizer and BMS have co-commercialized the blood thinner Eliquis since its December 2012 FDA approval, sharing development costs and splitting profits under a long-standing partnership. Eliquis was BMS's single largest product in 2025 at $14.4 billion in sales, and both companies face the same risk: Eliquis loses European patent protection in 2026 and U.S. exclusivity in 2028, which analysts expect to cut global sales by more than 90% by 2031.
Which is the better pharma stock, Pfizer or Bristol Myers Squibb?
Neither is better on every measure. Pfizer offers more diversification and scale, with $62.579 billion of 2025 revenue spread across vaccines, oncology and newer deals like Metsera and Innovent. Bristol Myers Squibb offers a higher net margin, 14.6% versus 12.4%, and a faster-growing Growth Portfolio, up 17% to $26.4 billion in 2025, but a bigger share of its revenue, 51% versus Pfizer's 36%, is tied to drugs facing patent cliffs by 2029.
Which company was founded first, Bristol-Myers Squibb Company or Pfizer Inc.?
Pfizer Inc. was founded in 1849; Bristol-Myers Squibb Company was founded in 1887.
What revenue did Bristol-Myers Squibb Company and Pfizer Inc. report?
Bristol-Myers Squibb Company had $48.2B (FY2025), while Pfizer Inc. had $62.6B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.
How do Bristol-Myers Squibb Company and Pfizer Inc. make money?
Bristol-Myers Squibb Company: Bristol Myers Squibb Company (BMS) discovers, develops, and delivers innovative medicines across four core therapeutic areas: Oncology, Hematology, Cardiovascular, and Immunology. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.
Which is better, Bristol-Myers Squibb Company or Pfizer Inc.?
There is no evidence-based single winner. Compare Bristol-Myers Squibb Company and Pfizer Inc. on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.
Sources & References
- SEC EDGAR: Bristol-Myers Squibb Company filings search (10-K, 8-K)
- Bristol-Myers Squibb Company Corporate Website
- Bristol-Myers Squibb Company 2025 revenue figure: sec.gov
- sec.gov
- bms.com
- morningstar.com
- data.sec.gov
- stockanalysis.com
- stockanalysis.com
- fda.gov
- finance.yahoo.com
- en.wikipedia.org
- SEC EDGAR: Pfizer Inc. filings search (10-K, 8-K)
- Pfizer Inc. Corporate Website
- Pfizer Inc. 2025 revenue figure: PFIZER INC annual report (Form 10-K, SEC EDGAR, filed 2026-02-26)
- sec.gov
- investors.pfizer.com
- pfizer.com
- investors.pfizer.com
- s206.q4cdn.com
- pfizer.com
- medicaloutcomes.pfizer.com
- ropesgray.com
- capital.com
Quick Answer
Pfizer is the bigger company by revenue, reporting $62.579 billion for fiscal 2025 against Bristol Myers Squibb's $48.194 billion, and it employs roughly 75,000 people versus BMS's 32,500. Bristol Myers Squibb is the more profitable of the two by margin: its $7.054 billion of 2025 net earnings equaled a 14.6% net margin, ahead of Pfizer's 12.4% margin on $7.771 billion of net income. By market value, Pfizer was worth about $157.7 billion as of September 18, 2026, versus roughly $130.2 billion for Bristol Myers Squibb as of September 10, 2026, according to Macrotrends.
Verdict
Pfizer is the larger, broader company, spanning vaccines, oncology, internal medicine and now obesity through its roughly $10 billion Metsera acquisition, while Bristol Myers Squibb is a narrower, more concentrated bet on oncology and the blood thinner Eliquis, which the two companies co-sell and which alone produced $14.4 billion of BMS's 2025 revenue. That concentration cuts both ways: BMS squeezed more profit from fewer, higher-value drugs, generating about $1.48 million of revenue per employee against Pfizer's roughly $834,000, but it is also more exposed to the 2028 loss of exclusivity on Eliquis and Opdivo, with analysts projecting a 21% revenue decline by 2029 versus 14% for Pfizer. Pfizer has been patching its pipeline through acquisitions and licensing deals such as Seagen, Metsera and the 2026 Innovent oncology collaboration, while BMS has leaned on its own run of deals, including Karuna, Mirati, RayzeBio and Orbital Therapeutics, plus cost cuts, to build a Growth Portfolio that reached $26.4 billion in 2025, up 17%. Neither company has solved its patent-cliff problem outright, but BMS is betting on a faster-growing, higher-margin portfolio to offset a bigger cliff, while Pfizer is betting on sheer scale and diversification.
Cite This Page
Automatically generated citations for researchers.
CorpDigest. (2026). Bristol-Myers Squibb Company vs Pfizer Inc. Comparison. from https://corpdigest.com/compare/bristol-myers-squibb-vs-pfizer
CorpDigest. "Bristol-Myers Squibb Company vs Pfizer Inc. Comparison." CorpDigest, 2026, https://corpdigest.com/compare/bristol-myers-squibb-vs-pfizer.
CorpDigest. "Bristol-Myers Squibb Company vs Pfizer Inc. Comparison." CorpDigest. 2026. https://corpdigest.com/compare/bristol-myers-squibb-vs-pfizer.